Pentamidine oral

Drug Profile

Pentamidine oral

Alternative Names: Oral OCZ103; VLX 103

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oncozyme Pharma
  • Developer Verlyx
  • Class Antifungals; Antineoplastics; Antiprotozoals; Benzamidines; Sulfonic acids
  • Mechanism of Action Endoexonuclease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alcoholic hepatitis; Non-alcoholic steatohepatitis
  • No development reported Hepatocellular carcinoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hepatocellular carcinoma in Canada (PO)
  • 30 Jun 2017 University of Massachusetts plans a phase I trial for Alcoholic hepatitis (NCT03201159)
  • 11 Nov 2016 Pharmacodynamics data from preclinical studies in Non-alcoholic steatohepatitis presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top